Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 25 
Cholinesterase activity in non-alcoholic-fatty liver disease in diabetic patients taking oral antidiabetic drugs
Ahmed A. J. Mahmood, Adnan A. Zainal, Musab M. Khalaf
Pages: 43 - 51
Number of pages: 9
Current Topics in Pharmacology
Volume 25 

Copyright © 2021 Research Trends. All rights reserved

Non-alcoholic fatty liver disease (NAFLD) and Alzheimer’s disease (AD) are common co-morbidities in patients with diabetes mellitus type 2 (T2DM). Resistance to insulin constitutes a major etiological factor for both conditions as well as in T2DM; thus, hypoglycemic drugs may show some promising prospect in this category of patients. Additionally, cholinesterases (ChEs), mainly butyrylcholinesterase (BChE) are, etiologically, a factor in both AD and DM; also, the effect of antidiabetic drugs on enzyme activity is a reasonable target for response. The present work aimed to investigate the effects of metformin and glibenclamide (MET-SU) with regard to acetylcholinesterase (AChE) and BChE activities and liver biochemical profile in 2 T2DM patient groups: those with a clinical picture of NAFLD and those free from NAFLD. The study is a case-control study, involving 3 groups (30 subjects each). Group 1 comprised of T2DM patients free from clinically evident NAFLD and group 2 comprised of T2DM patients newly diagnosed with NAFLD. The control group consisted of apparently healthy subjects. Groups 1 and 2 were on a metformin-glibenclamide (MET-SU) combination. AChE and BChE activities, as well as levels of transaminases, serum albumin, total bilirubin, alkaline phosphatase and fasting glucose serum levels were tested. AChE and BChE activity in groups 1 and 2 were significantly different compared to control, but much lower in group 2 compared to group 1 and control. In comparison to controls, plasma levels of transaminases, fasting glucose and alkaline phosphatase in group 2 showed a significant increase, while other parameters were not significantly different. We conclude that diabetic patients with NAFLD who are treated with a metformin-glibenclamide combination showed a better cholinesterase enzyme profile but less favorable liver function panel compared to other groups. These findings suggest a potential protective effect of the drugs in diabetic-NAFLD patients manifested as lowered cholinesterase activities, but they also indicate an apparent worsening of liver condition, in terms of biochemical parameters of liver function.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms